Skip to main content
. 2019 Dec 5;69(1):95–102. doi: 10.1007/s00262-019-02442-5

Fig. 1.

Fig. 1

Schema of illustrating the proposed trial design. Cohort, group, arm, and zone designation for the proposed study to test safety and immunogenicity of vaccination with the 12 class I major histocompatibility complex-restricted melanoma peptides (Mel12.1) with specified combinations of polyICLC (poly), incomplete Freund’s adjuvant (IFA), CD40 antibody, and with/without CD27 antibody (±)